A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?
Metrics: PDF 2133 views | Full Text 5549 views | ?
Erryk S. Katayama1, Jonathan J. Hue1,2, David L. Bajor3,4, Lee M. Ocuin5, John B. Ammori1,2, Jeffrey M. Hardacre1,2 and Jordan M. Winter1,2
1 Department of Surgery, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
2 Department of Surgery, University Hospitals Seidman Cancer Center and Case Comprehensive Cancer Center, Cleveland, Ohio, USA
3 Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
4 Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA
5 Division of Hepatobiliary and Pancreatic Surgery, Atrium Health, Charlotte, North Carolina, USA
|Jordan M. Winter,||email:||[email protected]|
Keywords: pancreatic cancer; pancreatic ductal adenocarcinoma; clinical trial; novel treatment; drug development
Received: June 20, 2020 Accepted: August 17, 2020 Published: September 22, 2020
Objective: Pancreatic cancer is the most aggressive common cancer and is desperately in need of novel therapies. Unlike many other common cancers, there have been no new paradigm-changing therapies in the past 40 years beyond multi-agent chemotherapy. In this study, we perform the first comprehensive analysis of the current clinical trial landscape in pancreatic cancer to better understand the pipeline of new therapies.
Materials and Methods: We queried
Results: As of May 18, 2019, there were 430 total active therapeutic interventional trials testing 590 interventions. The vast minority of trials (n = 37, 8.6%) are in phase III testing. 189 (31%) interventions are immunotherapies, 69 (11%) target cell signaling pathways, 154 (26%) target cell cycle or DNA biology, and 35 (6%) target metabolic pathways. Of the late phase trials, only 14 are currently testing novel interventions. Rather, 23 phase III trials examine new ways to deliver existing FDA-approved drugs, procedures, or pain management.
Conclusions: A large number of novel therapeutic strategies are currently under investigation. They include a broad range of therapies targeting diverse biologic processes. However, only a small number of novel therapies are in late-stage testing, suggesting that future progress is likely several years away, and dependent on the success of early-stage trials.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.